雙成藥業(002693.SZ)擬與中和藥業簽署產品權利轉讓協議 涉依替巴肽注射液
格隆匯 7 月 24日丨雙成藥業(002693.SZ)公佈，公司於2020年7月24日召開第四屆董事會第六次會議，會議審議通過了《關於公司簽署<產品權利轉讓協議>的議案》，同意公司擬以人民幣2800萬元將擁有與依替巴肽注射液(“轉讓產品”、“該產品”)有關的特定知識產權和生產技術在指定區域內的權利授予海南中和藥業股份有限公司(“中和藥業”)。
依替巴肽注射液用於急性冠狀動脈綜合徵(不穩定型心絞痛/非ST段抬高性心肌梗死)患者，包括接受藥物治療的患者和進行經皮冠狀動脈介入術(PCI)的患者，以降低死亡或新發生心肌梗死的聯合終點發生率；用於進行經皮冠狀動脈介入術(PCI)的患者，包括進行冠狀動脈內支架置入術的患者。以降低死亡、新發生心肌梗死或需要緊急介入治療的聯合終點發生率。
公司擁有與依替巴肽注射液有關的特定知識產權，合法擁有轉讓產品的生產技術，公司作為轉讓產品的藥品註冊申請人及藥品生產企業，已於2019年1月提交了合同產品的藥品上市許可註冊申請。目前已提交申請註冊的依替巴肽注射液產品規格為10ml:20mg/支及擬補充申請註冊的依替巴肽注射液產品規格為100ml:75mg/瓶。
根據北京亞超資產評估有限公司出具的《海南雙成藥業股份有限公司擬轉讓其擁有的“依替巴肽注射液”專有技術中國市場產品權利的所有權資產評估報告》【北京亞超評報字(2020)第A181號】(《評估報告》)，此次評估採用收益法對轉讓產品在評估基準日為2020年6月30日進行評估，依替巴肽注射液專有技術評估值為2600萬元，此次評估結論值為含增值税轉讓價。
公司將依替巴肽注射液有關的特定知識產權和生產技術在指定區域內的權利授予中和藥業不會影響公司業務的正常開展，也不涉及高層人員變動等情況，交易發生後不會導致與關聯方產生同業競爭的情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
